BioNTech acquires a former Novartis manufacturing facility in Singapore
Pfizer’s mRNA vaccine partner BioNTech is spreading its manufacturing reach across the globe, with its latest foothold in Southeast Asia.
BioNtech announced on Monday that its Singapore-based affiliate, BioNTech Pharmaceuticals Asia Pacific Pte. Ltd., had entered into an agreement with Novartis to acquire a GMP manufacturing facility in the country, with the move designed to grow its footprint in Asia.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.